Cancer Advisor

Last revised: June 2026 Integrative Oncology · Protocol Review A comprehensive synthesis of Dr Makis's clinical dosing regimens, benzimidazole combination strategies, the 2026 Hulscher observational cohort, pharmacokinetic rationale, safety monitoring requirements, and anonymised patient outcome data — presented with evidence grading. OneDayMD Editorial Team  |  Medically reviewed and updated  |  About Us Ivermectin combined with benzimidazoles (fenbendazole, mebendazole) represents an emerging area of repurposed oncology pharmacology. All protocols require physician supervision. Abstract Background: Dr William Makis MD (McGill Medicine; 110+ peer-reviewed publications) has treated cancer patients using repurposed antiparasitic agents since 2023, publicly documenting protocols and outcomes via Substack and X (@MakisMD). His approach centres on high-dos...

The paradigm of drug repurposing—identifying novel oncology applications for well-characterized, established medications—has become a cornerstone of innovative metabolic cancer strategies. Among the most deeply researched agents in this category is mebendazole (MBZ) . Originally developed as an FDA-approved anthelmintic to treat parasitic worm infections, contemporary preclinical models and clinical data show that mebendazole exerts a multi-axis metabolic attack on malignant cells, positioning it as a Tier 1 repurposed therapeutic in metabolic oncology. Executive Summary: Mebendazole works far beyond its traditional antiparasitic role. It targets cancer by destabilizing cellular infrastructure, shutting down tumor blood supply, halting cancer stem cells, and cutting off key metabolic fueling pathways like glycolysis and glutaminolysis. 1. The Multi-Axis Mechanisms of Mebendazole against Cancer Unlike standard targeted therapies that focus on a single genetic mutation, mebend...

Last updated: July 2026 Introduction Modified citrus pectin (MCP) is a low-molecular-weight form of citrus pectin designed for absorption. It has attracted attention because laboratory research suggests it may bind galectin-3, a protein involved in inflammation, fibrosis, immune regulation and cancer metastasis. Although preclinical evidence is encouraging, human clinical evidence remains limited and MCP should not be considered a proven cancer treatment. What is Modified Citrus Pectin? MCP is produced by altering natural citrus pectin into smaller fragments that are more readily absorbed than ordinary dietary pectin. Galectin-3 and Cancer Galectin‑3 is a β‑galactoside–binding lectin implicated in tumor cell aggregation, adhesion, angiogenesis, apoptosis resistance, immune evasion, and organ fibrosis.(2) Cell adhesion Tumor invasion Metastasis Angiogenesis Immune evasion How MCP May Work May interfere with galectin-3 mediated cell adhesion. May reduce metastatic spread in experimental...